{"doi":"10.18632/oncotarget.28099","title":"THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma","abstract":"// Phyllis A. Gimotty 1 , * , Jacob E. Till 2 , * , Shirsa Udgata 3 , Naomi Takenaka 3 , Stephanie S. Yee 2 , Michael J. LaRiviere 4 , Mark H. O’Hara 2 , Kim A. Reiss 2 , Peter O'Dwyer 2 , Bryson W. Katona 5 , Daniel Herman 6 , Erica L. Carpenter 2 and Kenneth S. Zaret 3 1 Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 2 Division of Hematology-Oncology, Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 3 Institute for Regenerative Medicine, Department of Cell and Developmental Biology, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA 4 Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 5 Division of Gastroenterology, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 6 Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA * These authors contributed equally to this work Correspondence to: Kenneth S. Zaret, email: zaret@pennmedicine.upenn.edu Erica L. Carpenter, email: erical@upenn.edu Keywords: pancreatic cancer; metastasis; biomarkers; prognosis; THBS2 Received: July 19, 2021     Accepted: October 10, 2021     Published: October 26, 2021 Copyright: © 2021 Gimotty et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Patients newly diagnosed with metastatic pancreatic ductal adenocarcinoma generally have poor survival, with heterogeneous rates of progression. Biomarkers that could predict progression and/or survival would help inform patients and providers as they make care decisions. In a previous retrospective study, we discovered that circulating thrombospondin-2 (THBS2) could, in combination with CA19-9, better distinguish patients with PDAC versus healthy controls. Here we evaluated whether THBS2 levels, previously not known to be prognostic, were associated with outcome in 68 patients at time of diagnosis of metastatic PDAC. Specifically, we interrogated the association of THBS2 level, alone or in combination with CA19-9, with progression by 90 days and/or survival to 180 days. The results indicate that elevated THBS2 levels alone, at the time of a metastatic PDAC diagnosis, can identify patients with a shorter time to death and thus help patients and providers when planning treatment.","journal":"Oncotarget","year":2021,"id":203889,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":5,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9566,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":473198,"name":"Jacob E. Till","orcid":"0000-0002-2824-1282","position":1,"is_corresponding":false},{"id":506847,"name":"Shirsa Udgata","orcid":"0000-0002-1929-8121","position":2,"is_corresponding":false},{"id":290570,"name":"Naomi Takenaka","orcid":null,"position":3,"is_corresponding":false},{"id":473199,"name":"Stephanie S. Yee","orcid":"0000-0002-3469-9775","position":4,"is_corresponding":false},{"id":637106,"name":"Michael J. LaRiviere","orcid":"0000-0002-1662-5086","position":5,"is_corresponding":false},{"id":109505,"name":"Mark H. O’Hara","orcid":"0000-0003-2751-6122","position":6,"is_corresponding":false},{"id":258296,"name":"Kim A. Reiss","orcid":"0000-0003-0774-9914","position":7,"is_corresponding":false},{"id":74906,"name":"Peter J. O’Dwyer","orcid":"0000-0002-9302-4073","position":8,"is_corresponding":false},{"id":245660,"name":"Bryson W. Katona","orcid":"0000-0001-8186-9119","position":9,"is_corresponding":false},{"id":317434,"name":"Daniel S. Herman","orcid":"0000-0003-2873-587X","position":10,"is_corresponding":false},{"id":251374,"name":"Erica L. Carpenter","orcid":"0000-0002-0735-3605","position":11,"is_corresponding":false},{"id":98970,"name":"Kenneth S. Zaret","orcid":"0000-0001-8932-3145","position":12,"is_corresponding":false},{"id":325359,"name":"Phyllis A. Gimotty","orcid":"0000-0002-3850-9799","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-18T23:51:22.166488Z","pmid":"34733417","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}